Molecular structure of Canagliflozin, CAS Number: 842133-18-0
Canagliflozin (CAS 842133-18-0)
See product citations (2)
Alternate Names:
Canagliflozin is also known as JNJ 28431754.
Application:
Canagliflozin is a selective SGLT-2 Inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
CAS Number:
842133-18-0
Purity:
≥98%
Molecular Weight:
444.52
Molecular Formula:
C24H25FO5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Canagliflozin is a selective SGLT-2 Inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively. Canagliflozin inhibits Na+- dependent 14C-AMG uptake in a concentration-dependent fashion. Canagliflozin is a novel C-glucoside with thiophene ring. Canagliflozin inhibits the facilitative GLUT-mediated H020DG uptake in L6 myoblasts. Canagliflozin reduces blood glucose levels, respiratory exchange ratio, and body weight gain in DIO mice. Canagliflozin increases urinary glucose excretion with no significant change in total food intake compare with that in vehicle-treated rats, leading to a decrease in body weight in ZF rats.
Canagliflozin (CAS 842133-18-0) References
- Canagliflozin-Associated Acute Pancreatitis. | Verma, R. 2016. Am J Ther. 23: e972-3. PMID: 25187092
- The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. | Jojima, T., et al. 2019. Int J Mol Sci. 20: PMID: 31652578
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. | Li, J., et al. 2020. Kidney Int. 98: 769-777. PMID: 32470492
- Canagliflozin and cardiovascular outcomes in Type 2 diabetes. | Sarraju, A., et al. 2021. Future Cardiol. 17: 39-48. PMID: 32748638
- Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. | Blonde, L., et al. 2021. Adv Ther. 38: 594-606. PMID: 33180317
- Canagliflozin: metabolic, cardiovascular and renal protection. | Barrios, V. and Escobar, C. 2021. Future Cardiol. 17: 443-458. PMID: 33538620
- Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. | Reifsnider, OS., et al. 2021. BMJ Open Diabetes Res Care. 9: PMID: 33941549
- Effects of canagliflozin on human myocardial redox signalling: clinical implications. | Kondo, H., et al. 2021. Eur Heart J. 42: 4947-4960. PMID: 34293101
- Canagliflozin Increases Intestinal Adenoma Burden in Female ApcMin/+ Mice. | Korfhage, J., et al. 2022. J Gerontol A Biol Sci Med Sci. 77: 215-220. PMID: 34448851
- Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice. | Lv, XH., et al. 2022. Acta Pharmacol Sin. 43: 2651-2665. PMID: 35217814
- Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. | Xu, Z., et al. 2022. Yonsei Med J. 63: 619-631. PMID: 35748073
- SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. | Long, Q., et al. 2022. Int Immunopharmacol. 110: 109024. PMID: 35841866
- Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. | Peyton, KJ., et al. 2022. Int J Mol Sci. 23: PMID: 35955910
- Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy. | Du, S., et al. 2022. Front Endocrinol (Lausanne). 13: 1011669. PMID: 36313744
- Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice. | Zuo, Q., et al. 2022. Drug Des Devel Ther. 16: 4161-4177. PMID: 36510490
Inhibitor of:
HKDC1, hnRNP E3, Insulin, KCC1, NaGLT1, Olr408, Pancreatic Icosapeptide, QRFP, Sg II, SGLT-1, SGLT-2, SGLT-5, SGLT-6, and SLU7.Activator of:
CPA4, NaGLT1, SGLT-3, and SLC5A12.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Canagliflozin, 5 mg | sc-364454 | 5 mg | $312.00 | |||
Canagliflozin, 50 mg | sc-364454A | 50 mg | $416.00 |